BCL2 and cancer: Small molecules that antagonize pro-survival Bcl-2 proteins, namely BH3 mimetics, are currently under pre-clinical and clinical evaluation as single agent anti-cancer therapies and as sensitizers to apoptosis-inducing drugs [33, 34].